10.1053/j.gastro.2015.12.037 [DOI] [PMC free article] [PubMed] [Google Scholar] 83.Ibrahim SH, Hirsova P, Tomita K, Bronk SF, Werneburg NW, Harrison SA, et al
Collins, S
Your doctor can run a simple blood test to verify a deficiency is to blame
Depression Major depressive disorder (MDD) affects 4.217% of populations worldwide, and is a common cause of disability
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
